1
项与 Autologous aPD-L1 armored anti-CD22 CAR-T cells (Hebei Senlang Biotechnology) 相关的临床试验Feasibility and Safety of Anti-PD-L1 Armored Anti-CD22 CAR-T/CAR-TILs Targeting Patients With Solid Tumors
This is an open-labeled, single-armed and prospective study, patients with advanced malignant solid tumors will be given with SL22P autologous CAR - T/CAR-TILs cells. The aim of the study is to evaluate the safety and efficacy of SL22P CAR-T cells, including the adverse reaction, pharmacokinetics, and the outcomes of patients.
100 项与 Autologous aPD-L1 armored anti-CD22 CAR-T cells (Hebei Senlang Biotechnology) 相关的临床结果
100 项与 Autologous aPD-L1 armored anti-CD22 CAR-T cells (Hebei Senlang Biotechnology) 相关的转化医学
100 项与 Autologous aPD-L1 armored anti-CD22 CAR-T cells (Hebei Senlang Biotechnology) 相关的专利(医药)
100 项与 Autologous aPD-L1 armored anti-CD22 CAR-T cells (Hebei Senlang Biotechnology) 相关的药物交易